TY - JOUR
T1 - Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis
AU - Kramer, Mario W.
AU - Escudero, Diogo O.
AU - Lokeshwar, Soum D.
AU - Golshani, Roozbeh
AU - Ekwenna, Obi O.
AU - Acosta, Kristell
AU - Merseburger, Axel S.
AU - Soloway, Mark
AU - Lokeshwar, Vinata B.
N1 - Copyright:
Copyright 2011 Elsevier B.V., All rights reserved.
PY - 2011/3/15
Y1 - 2011/3/15
N2 - BACKGROUND: Cancer biomarkers are the backbone for the implementation of individualized approaches to bladder cancer (BCa). Hyaluronic acid (HA) and all 7 members of the HA family, that is, HA synthases (HA1, HA2, HA3), HYAL-1 hyaluronidase, and HA receptors (CD44s, CD44v, and RHAMM), function in tumor growth and progression. However, the diagnostic and prognostic potential of these 7 HA family members has not been compared simultaneously in any cancer. We evaluated the diagnostic and prognostic potential of HA family members in BCa. METHODS: Using quantitative PCR and immunohistochemistry, expression of HA family members was evaluated in prospectively collected bladder tissues (n = 72); mean and median follow-up were 29.6 ± 5.3 and 24 months, respectively. Transcript levels were also measured in exfoliated urothelial cells from urine specimens (n = 148). RESULTS: Among the HA family members, transcript levels of the HA synthases, HYAL-1, CD44v, and RHAMM were 4- to 16-fold higher in BCa tissues than in normal tissues (P <.0001); however, CD44s levels were lower. In univariate and multivariate analyses, tumor stage (P =.003), lymph node invasion (P =.033), HYAL-1 (P =.019), and HAS1 (P =.027) transcript levels, and HYAL-1 staining (P =.021) were independently associated with metastasis. Tumor stage (P =.019) and HYAL-1 (P =.046) transcript levels were also associated with disease-specific mortality. Although HA synthase and HYAL-1 transcript levels were elevated in exfoliated urothelial cells from BCa patients, the combined HAS2-HYAL-1 expression detected BCa with an overall sensitivity of 85.4% and a specificity of 79.5% and predicted BCa recurrence within 6 months (P =.004; RR = 6.7). CONCLUSIONS: HYAL-1 and HAS1 expression predicted BCa metastasis, and HYAL-1 expression also predicted disease-specific survival. Furthermore, the combined HAS2-HYAL-1 biomarker detected BCa and significantly predicted its recurrence.
AB - BACKGROUND: Cancer biomarkers are the backbone for the implementation of individualized approaches to bladder cancer (BCa). Hyaluronic acid (HA) and all 7 members of the HA family, that is, HA synthases (HA1, HA2, HA3), HYAL-1 hyaluronidase, and HA receptors (CD44s, CD44v, and RHAMM), function in tumor growth and progression. However, the diagnostic and prognostic potential of these 7 HA family members has not been compared simultaneously in any cancer. We evaluated the diagnostic and prognostic potential of HA family members in BCa. METHODS: Using quantitative PCR and immunohistochemistry, expression of HA family members was evaluated in prospectively collected bladder tissues (n = 72); mean and median follow-up were 29.6 ± 5.3 and 24 months, respectively. Transcript levels were also measured in exfoliated urothelial cells from urine specimens (n = 148). RESULTS: Among the HA family members, transcript levels of the HA synthases, HYAL-1, CD44v, and RHAMM were 4- to 16-fold higher in BCa tissues than in normal tissues (P <.0001); however, CD44s levels were lower. In univariate and multivariate analyses, tumor stage (P =.003), lymph node invasion (P =.033), HYAL-1 (P =.019), and HAS1 (P =.027) transcript levels, and HYAL-1 staining (P =.021) were independently associated with metastasis. Tumor stage (P =.019) and HYAL-1 (P =.046) transcript levels were also associated with disease-specific mortality. Although HA synthase and HYAL-1 transcript levels were elevated in exfoliated urothelial cells from BCa patients, the combined HAS2-HYAL-1 expression detected BCa with an overall sensitivity of 85.4% and a specificity of 79.5% and predicted BCa recurrence within 6 months (P =.004; RR = 6.7). CONCLUSIONS: HYAL-1 and HAS1 expression predicted BCa metastasis, and HYAL-1 expression also predicted disease-specific survival. Furthermore, the combined HAS2-HYAL-1 biomarker detected BCa and significantly predicted its recurrence.
UR - http://www.scopus.com/inward/record.url?scp=79952402793&partnerID=8YFLogxK
U2 - 10.1002/cncr.25565
DO - 10.1002/cncr.25565
M3 - Journal articles
C2 - 20960509
AN - SCOPUS:79952402793
SN - 0008-543X
VL - 117
SP - 1197
EP - 1209
JO - Cancer
JF - Cancer
IS - 6
ER -
